Abstract
This extensive study explores the field of novel biomarkers for the early detection of cardiovascular disease (CVD), looking at a variety of indicators, including circulating endothelial cells, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein (hs-CRP), microRNAs, and myeloperoxidase (MPO). The review emphasizes how important these indicators are to improving CVD risk assessment, prognosis, and treatment plans. While each biomarker offers distinct insights into particular facets of cardiovascular health, multi-biomarker panel integration is suggested for a more thorough knowledge. The paper also discusses the difficulties with standardization, moral issues, and legal restrictions related to using these biomarkers in therapeutic settings. In addition, the revolutionary potential of these new biomarkers in conjunction with state-of-the-art technologies is emphasized, providing a promising path towards precision cardiovascular care and customized medicine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
